London, Ontario, Canada, May 13, 2024 – Alimentiv Inc. (“Alimentiv”) is pleased to announce two lecture presentations and six poster presentations at the Digestive Disease Week (DDW) Meetings and Trade Show taking place May 18-21, 2024 at the Walter E. Washington Convention Center in Washington, D.C.

Alimentiv is a globally recognized leader in outcome measures development, multi-center clinical trials, and centralized imaging solutions. It is also a trusted partner of the pharmaceutical and biotechnology industries and medical research centers. Our collaborative approach, deep GI therapeutic expertise, and exceptional organizational and communication skills foster a responsive, client-driven approach. 

Our collaborative approach extends to a global network of gastrointestinal expert collaborators & KOLs, engaging in outcome measure development and validation programs and facilitating implementation within clinical trials.

“We are committed to the leadership in GI research and proud to work with industry leaders whose research is instrumental in progressing clinical development programs and treatments for patients living with GI-related illnesses,” said Dr. Gabriela Radulescu, Vice President, Medical Research and Development.

Lecture presentations include:

Disease Clearance After 16 Weeks Of Treatment With Vedolizumab In Patients With Moderate To Severe Ulcerative Colitis: An Interim Analysis From The Verdict Trial | Presentation #905 | Presenter: Dr. Vipul Jairath

Development Of A Digital Pathology Analysis Algorithm To Augment the Quantification Of Peak Eosinophil Count In Biopsies From Patients With Eosinophilic Esophagitis | Presentation #961 | Presenter: Dr. Pavine Lefevre

Poster sessions include:

Comparative Responsiveness Of Disease Activity Indices In Moderately-To-Severely Active Ulcerative Colitis: A Post-Hoc Analysis Of The Unifi Trial Performance Of Bowel Preparation Quality Scales In Patients With Crohn’s Disease | Poster #Sa1789 | Presenter: Dr. Virginia Solitano

Placebo Rates In Crohn’s Disease: An Individual Patient Data Meta-Analysis From Multiple Randomized Controlled Trials | Poster #Su1758 | Presenter: Dr. Virginia Solitano

Spatial Transcriptomics Reveals Cellular Niches Associated With Histological Inflammation In Postoperative Crohn’s Disease | Poster #Tu1747 | Presenter: Dr. Robert Battat

Transcriptomic Signature Of Response To Vedolizumab In Patients With Moderate-To-Severe Ulcerative Colitis: Results From An International, Multicenter, Retrospective Cohort Study | Poster #Tu1768 | Presenter: Dr. Niels Vande Casteele

“Metabolism And Response To Stress” (Mars) Gene Signatures Reveal Heterogeneity In Patients With Ulcerative Colitis And Identify Characteristics Of Patients With Increased Response To Therapy | Poster #Mo1795 | Presenter: Dr. Niels Vande Casteele

Performance Of Bowel Preparation Quality Scales In Patients With Crohn’s Disease | Poster #Mo2031 | Presenter: Dr. Virginia Solitano

See the full schedule

Visit Alimentiv at Booth #2105 to engage with our experts and explore how Alimentiv can support your research objectives.

About Alimentiv Inc.

Alimentiv is a global gastroenterology-focused contract research organization (CRO) providing clinical trials, central image management, precision medicine, statistics, and laboratory services to the pharmaceutical and biotechnology industries. Headquartered in London, Ontario, Alimentiv employs more than 500 people across its operations in Canada, the United States, Europe, Asia-Pacific, and Latin America. The organization’s unique model combines the efforts of internationally recognized academic researchers and operational experts to offer integrated solutions to customers. Over the past 30 years, Alimentiv has become a recognized expert in clinical trial design, central image management solutions, outcome measure development, and precision medicine for drug development in GI. Today, Alimentiv provides services in more than 60 countries worldwide, collaborates with leading universities and academic institutions across the globe, and works with many leading pharmaceutical and biotechnology organizations to bring new and improved treatment options to patients. Alimentiv is committed to investment in medical research and development, focusing on identifying barriers to drug development and pursuing solutions that advance GI research. The research findings are operationalized into an efficient clinical trial methodology for clients that aligns with emerging regulatory standards. In collaboration with leading experts, Alimentiv has pioneered the development, validation, and standardization of outcome measures and technology, shaping the evolving clinical trial landscape for multiple indications and providing meaningful long-term consequences for patients, their treatment, and society. For more information, visit: